Establishment Labs (ESTA) Expected to Announce Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Establishment Labs to announce earnings of ($0.3368) per share and revenue of $65.7910 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s quarterly revenue was up 44.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.70) earnings per share. On average, analysts expect Establishment Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Establishment Labs Stock Performance

Establishment Labs stock opened at $94.61 on Wednesday. Establishment Labs has a fifty-two week low of $33.35 and a fifty-two week high of $97.59. The firm’s 50 day simple moving average is $85.77 and its 200-day simple moving average is $73.97. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The company has a market cap of $2.78 billion, a P/E ratio of -63.50 and a beta of 1.07.

Institutional Trading of Establishment Labs

Several institutional investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC acquired a new position in Establishment Labs in the 4th quarter valued at approximately $47,000. Quarry LP acquired a new stake in shares of Establishment Labs during the 3rd quarter valued at $34,000. Osaic Holdings Inc. boosted its stake in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares during the period. Twinbeech Capital LP purchased a new position in shares of Establishment Labs during the 4th quarter valued at $214,000. Finally, Farallon Capital Management LLC purchased a new position in shares of Establishment Labs during the 4th quarter valued at $219,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. BTIG Research reaffirmed a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Mizuho increased their target price on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Citigroup increased their target price on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Finally, TD Cowen raised their target price on Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a research report on Monday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.75.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.